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Abstract
Background: The clinical manifestations of severe asthma are heterogeneous. Some individuals with severe
asthma develop irreversible fixed airway obstruction, which is associated with poor outcomes. We therefore
investigated the factors associated with fixed airway obstruction in Korean patients with severe asthma.
Methods: Severe asthma patients from a Korean adult asthma cohort were divided into two groups according to
the results of serial pulmonary function tests. One group had fixed airway obstruction (FAO) [forced expiratory
volume in 1 second (FEV1)/forced vital capacity (FVC) ratio < 0.7, n = 119] and the other had reversible airway
obstruction (RAO) [FEV1/FVC ratio ≥ 0.7, n = 116]. Clinical and demographic parameters were compared between
the two groups.
Results: Multivariate analysis showed that longer duration of disease, greater amount of cigarette smoking and
absence of rhinosinusitis were significantly related to the development of FAO in severe asthmatics. Other
parameters, including atopic status, pattern of airway inflammatory cells in induced sputum, and frequency of
asthma exacerbations did not differ between the FAO and RAO groups.
Conclusion: Severe asthma patients with longer disease duration and the absence of rhinosinusitis are more likely
to develop FAO. This study also demonstrates the importance of quitting smoking in order to prevent irreversible
airway obstruction. Further investigation is required to determine the mechanism by which these factors can
modify the disease course in Korean patients with severe asthma.
Introduction
Asthma, as a chronic airway inflammatory disease, is
characterized by recurrent episodes of symptomatic
reversible airflow obstruction and airway hyperreactivity
to nonspecific stimuli. The early use of inhaled corticos-
teroids, which reduce airway inflammation and improve
pulmonary function, is remarkably effective to control
asthma symptoms in these patients[1,2]. However, a
subset of asthmatic patients does not respond well to
inhaled corticosteroids; most of these patients therefore
show uncontrolled asthma symptoms despite treatment
with anti-asthmatic medications. Although only 5% of
individuals with asthma have severe asthma, they suffer
from associated morbidities and show poor quality of
life. Furthermore, almost 50% of the healthcare costs for
all asthma patients were spent for the treatment of
severe asthma [3]. Treatment of severe asthma, there-
fore, has become a major challenge for physicians.
The effective management of severe asthma requires a
thorough understanding of its pathobiology. Clinical
manifestations in patients with severe asthma can vary
widely [4,5]. Among the clinical characteristics of severe
asthma are its progression to irreversible airway obstruc-
tion and its poor response to glucocorticoid therapy.
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lung function, which may be related to fixed airway
obstruction (FAO). In contrast, other severe asthma
patients maintain pulmonary function. FAO has been
reported in up to 50% of patients with severe asthma
[6]. FAO has also been associated with poor long-term
prognosis since patients with this phenotype show a
continuous decline in lung function and a high fre-
quency of asthma exacerbations [7].
Modification of factors causing FAO may be critical
in preventing morbidities in severe asthmatics with
FAO. Among the patient characteristics found to be
risk factors for FAO are advanced age, male sex, smok-
ing, longer asthma duration, aspirin sensitivity and
sputum eosinophilia [6,8]. Asthma is a multifactorial
disorder, with clinical features affected by both genetic
and environmental factors. Thus, the risk factors
related to FAO in Korean patients with severe asthma
may differ from factors associated with FAO in
patients from other countries. To date, however, the
clinical characteristics of severe asthma patients with
FAO in Korea have not been reported. We therefore
assessed the clinical features of patients with severe
asthma and FAO in an adult asthma cohort recently
analyzed in Korea [9]. To determine the clinical factors
associated with FAO, we compared the clinical features
in severe asthma patients with FAO with those in
severe asthma patients with reversible airway obstruc-
tion (RAO).
Materials and methods
Study subjects
The COREA (COhort for Reality and Evolution of adult
Asthma in Korea) is a prospective, observational, multi-
center cohort of Korean adults with asthma designed to
investigate the characteristics of Korean asthma patients
[9]. The study subjects are 14 years or older and have
been suffering from at least one of the chronic, persis-
tent, respiratory symptoms of dyspnea, cough, sputum
production or wheezing for more than three months.
Asthma was then diagnosed by demonstration of airway
reversibility or bronchial hyperresponsiveness (BHR).
Airway reversibility consisted of an improvement in
FEV1 of at least 12% post-bronchodilator (200 mcg of
albuterol by means of a metered-dose inhaler), or 20%
or more over time or after corticosteroid treatment.
BHR was defined as PC20 (provocation concentration
that caused a decrease in FEV1 of 20%) of methacholine
≤ 16 mg/mL before asthma treatment [10]. In order to
exclude smoking-related COPD, patients with apparent
emphysema based on simple chest radiography were
excluded and every asthma subject was diagnosed by
experienced clinicians in the field of allergy or pulmo-
nology at each institution.
Inclusion criteria of this study
A total of 1,520 asthma patients were registered by the
11 centers; of these, 352 patients were classified as
severe asthma by the clinicians and finally 235 patients
were selected for the study. Detailed criteria for the
enrollment were as follows: 1) all patients should have
one of the following clinical components including an
FEV1 less than 60% of the predicted value, daily symp-
toms, frequent exacerbations, frequent nocturnal symp-
toms, and limited physical activity (based primarily on
Global Initiative for Asthma (GINA) 2002 guidelines
[2]); 2) requirement for treatment should be moderate-
to high-dose ICS and an LABA combination inhaler
with or without sustained-release theophylline, leuko-
triene modifier, oral ß2 agonist or oral glucocorticoids;
3) the patients should undergo all 3 pulmonary function
tests under stable conditions without asthma exacerba-
tion at the time of enrollment (baseline) and at 3 and
12 months after enrollment. Among those 3 pulmonary
function tests, at least one test was performed both
before and after inhalation of 200 microgram of albu-
terol on top of ICS and LABA; 4) all the patients were
believed to be adequately treated and adherent to pre-
scribed medications.
Exclusion criteria of the study
Patients with acute exacerbated asthma or any missing
spirometry data among the 3 visits (baseline and 2 fol-
low-up visits) were excluded. Patients with any of the
following conditions were also excluded; 1) serious
non-pulmonary diseases such as heart failure, cancers
and severe psychiatric disorders; 2) other pulmonary
diseases such as apparent emphysema, bronchiectasis,
or destroyed lung caused by previous medical condi-
tions like pulmonary tuberculosis on chest radiogra-
phy. Figure 1 summarizes these inclusion/exclusion
criteria.
Definition of fixed airway obstruction and reversible
airway obstruction
Patients with severe asthma were classified into two
groups, those with FAO and those with RAO, based on
the results of their pulmonary function tests. FAO was
defined as an FEV1/FVC ratio < 0.7 on all of three pul-
monary function tests despite use of high-dose inhaled
corticosteroids (ICS) and long-acting b2-agonists
(LABA)[8,11]. RAO was defined when an FEV1/FVC
ratio > 0.7 was proved on at least one pulmonary func-
tion test.
Study design
Demographic and clinical data recorded at the time of
enrollment included asthma duration, age at asthma
onset, the number of episodes of asthma exacerbation,
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laboratory tests. Pulmonary function tests were per-
formed at the time of enrollment and 3 and 12 months
later. Baseline methacholine bronchial provocation tests
were performed in some patients (33 in FAO and 32 in
RAO, respectively) with PC20, being an indicator of
bronchial hyperresponsiveness (BHR).
The episodes of exacerbation, emergency department
visits, and hospitalizations were determined based on
the patients’ responses to questions such as, ‘Have you
ever visited any hospital or emergency room or ever
been hospitalized because of suddenly worsening asth-
matic symptoms, such as dyspnea and wheezing?’.I n
addition, the presence of rhinosinusitis was defined
according to the patients’ medical history in a simple
questionnaire which included the questions: ‘Have you
ever been diagnosed with chronic allergic rhinosinusitis?’
and ‘Have you recently had one or more symptoms of
nasal congestion, including runny nose, sneezing, nasal
itching, and post-nasal drip?’. Rhinoscopy or radiologic
studies were not routinely performed.
A skin prick test was conducted using the common
inhalant allergens in Korea, including Dermatophagoides
pteronyssinus, Dermatophagoides farinae, tree pollen
mixtures, grass pollen mixtures, ragweed, mugwort, cat
fur, dog fur, cockroach, aspergillus, alternaris, and other
fungus mixtures (Allergopharma, Darmstadt, Germany),
and if any positive response was found in the skin test,
we defined the subject as having atopy.
In our study, the induced sputum analysis was con-
ducted at enrollment according to the method pre-
viously described [12]. In brief, sputum induction was
performed by inhalation of hypertonic saline (NaCl
4.5%) for 15 min after premedication with inhaled albu-
terol. The sputum was treated with dithiothreitol and
phosphate buffered saline and was then centrifuged at
1,000 rpm for 10 min. Cells were stained with Diff-Quik
(American Scientific Products, McGaw, IL, U.S.A.).
Methacholine bronchial provocation test was per-
formed using a dosimeter-controlled jet nebulizer with
increasing doses of methacholine from 0.625 to 25 mg/
mL. Each dose of methacholine was inhaled during five,
slow and vital-capacity breaths. At one and three min-
utes after each set of inhalations, spirometry was
recorded. The interval between one dose and the next
was five minutes.
COREA (n=1520) 
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Figure 1 Flowchart showing selection of patients with severe asthma.
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FAO, all parameters were compared between the FAO
and RAO groups. To determine whether the 235
patients analyzed were representative of the entire
cohort of 352 subjects with severe asthma, the clinical
characteristics of the 117 unselected and 235 selected
patients were compared. The study protocol was
approved by the institutional review boards of all parti-
cipating hospitals. (Asan Medical Center, University of
Ulsan; Seoul National University Hospital; Bundang
Seoul National University Hospital; Yonsei University
Hospital; Chungang University Hospital; Ewha Womans
University Hospital; Hanyang University Hospital;
Soonchunhyang University Hospital; Ajou University
Hospital; ChonBuk National University Hospital).
Statistical methods
Fisher’s exact tests and c
2 tests were used to compare
categorical variables and independent Student’s t-tests
were used to compare continuous variables. The Mann-
Whitney U-test was also used to compare continuous
variables that did not follow a normal distribution. Each
variable was assessed in the univariate analyses. Vari-
ables showing a significant correlation (p ≤ 0.1) were
included in the multivariate logistic regression analysis.
Smoking (≥ 5 pack-years vs < 5 pack-years)[13,14],
asthma duration (≥ 15 years vs < 15 years)[15], rhinitis,
patient age (≥ 50 years old vs < 50 years old) [16,17],
age at onset (≥ 40 years old vs < 40 years old)[18], and
gender and atopic status which were selected for identi-
fication of the independent factors associated with FAO.
Statistical analyses were performed using the SPSS sta-
tistical software package (version 18). P < 0.05 was con-
sidered statistically significant.
Results
Of 235 patients with severe asthma, 119 (51%) had FAO
and 116 had RAO (Figure 1). The baseline characteris-
tics of the two groups are shown in Tables 1, 2 and 3.
Patients with FAO were significantly older than
those with RAO (58.3 ± 12.8 years vs 47.1 ± 14.3
years, p < 0.001). In addition, patients with FAO were
more likely to be male (64% vs 40%, p < 0.001), have a
later age of asthma onset (47.5 ± 15.4 years vs 39.7 ±
15.6 years, p < 0.001) and have a longer smoking his-
tory (30 [18.7 - 40] pack-years vs 14 [4.5 - 25] pack-
years, p < 0.001). Symptoms of rhinosinusitis were sig-
nificantly less common in patients with FAO than in
patients with RAO (50% vs 66%, p = 0.014). There
were no significant between-group differences in treat-
ment duration, numbers of emergency department vis-
its and admissions due to acute asthma exacerbation,
BMI (kg/m
2), atopic status and history of asthma
exacerbation (Table 1).
The initial percent predicted FEV1 was significantly
lower in the FAO than in the RAO group (54.8 ± 19.9%
vs 74.3 ± 22.5%, p < 0.001), as were initial (56.3 ± 11.1%
vs 77.6 ± 10.6%, p < 0.001) and best (58.9 ± 9.6% vs
80.9 ± 7.1%, p < 0.001) FEV1/FVC ratios after treatment
(3 or 12 months after enrollment) and PC20 values (2.7
± 4.1 mg/dL vs 5.6 ± 6.4 mg/dL, p = 0.036) (Table 2).
We found that there were no between-group differ-
ences in serum concentrations of total IgE, CRP and
uric acid. Complete blood cell analysis showed no signif-
icant between group differences in neutrophil and eosi-
nophil counts, and there were no differences in induced
sputum analysis (Table 3).
Multivariate analysis identified several independent
factors associated with FAO (Table 2). Smoking was the
most potent independent factor associated with FAO,
with an adjusted odds ratio (OR) for smoking more
than 5 pack-years of cigarettes of 6.6 [95% confidence
interval (CI), 1.4 to 30.1]. In addition, FAO was asso-
ciated with long standing (> 15 years) asthma (adjusted
OR, 5.3; 95% CI, 1.2 to 23.8) and an absence of rhinosi-
nusitis (adjusted OR, 3.8; 95% CI, 1.2 to 12.1). Advanced
age, late-onset asthma, presence of asthma exacerbation
history, male sex and presence of atopy were not inde-
pendently associated with the development of FAO in
multivariate analysis (Table 4).
When we compared the 235 study subjects and the
117 patients with severe asthma who were not enrolled
Table 1 Demographic data of patients with severe
asthma
Characteristics FAO
(n = 119)
RAO
(n = 116)
P-value
Age, yr 58.3 ± 12.8 47.1 ± 14.3 <0.001
Male, % 64 40 <0.001
BMI, kg/m
2 23.4 ± 2.9 23.9 ± 3.5 0.239
Duration of asthma, yr 10 [4 - 18] 6 [3 - 12] 0.083
Onset age, yr 47.5 ± 15.4 39.7 ± 15.6 <0.001
Treatment duration, yr 5 [2 - 10] 5 [3 - 10] 0.851
Numbers of ER visit due to asthma 2 [1 - 5] 2 [1 - 5] 0.751
Numbers of admission due to
asthma
2 [1 - 5] 1 [1 - 4] 0.070
Presence of exacerbation, % 51 58 0.339
Presence of atopy, % 34 49 0.068
Presence of rhinosinusitis, % 50 66 0.014
Duration of smoking, pack-years 30 [18.7 -
40]
14 [4.5 - 25] <0.001
Smoking, current/ex/non, n 15/61/24 14/42/44 0.003
Abbreviations:
FAO, fixed airway obstruction; RAO, reversible airway obstruction; ER,
emergency room.
Data are presented as mean ± SD, % or median [interquartile range].
P-values were determined using the Mann-Whitney U-test, chi-square or
Fisher’s test.
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with rhinosinusitis was lower in selected than in non-
selected patients (58% vs 72%, p = 0.021) and that age
at asthma onset was higher in selected than in non-
selected patients (43.7 ± 16.0 years vs 40.1 ± 16.3 years,
p = 0.037). Other clinical and demographic characteris-
tics, however, did not differ significantly between the
two groups (data not shown).
Discussion
We have shown here that longer asthma duration and
the absence of rhinosinusitis, in addition to cigarette
smoking, are independent factors associated with the
development of irreversible FAO in Korean patients
with severe asthma. Although effective methods to
improve the management of patients with severe asthma
remain a challenge for physicians, the results presented
here provide further evidence of the importance of quit-
ting smoking in preventing irreversible airway obstruc-
tion, especially in patients with severe asthma [19].
These results also indicate that patients with a certain
subtype of severe asthma, without upper airway
p a t h o l o g ys u c ha sr h i n o s i n u s i t i s ,a r em o r el i k e l yt o
develop irreversible airway obstruction. Moreover, our
findings highlight the significance of understanding the
heterogeneity of severe asthma and suggest that the
pathogenesis of severe asthma without rhinosinusitis
might differ from that of severe asthma with rhinosinu-
sitis. Clarification of the mechanisms underlying certain
subtypes of severe asthma may provide clues to thera-
peutic strategies for overcoming this condition.
Although only a small proportion of patients with
asthma have severe asthma, this subtype of asthma is
associated with most asthma-related morbidities and
asthma-associated costs [3]. Severe asthma is character-
ized by frequent asthma attacks, resistance to high-dose
ICS treatment and fixed irreversible airway obstruction
[20]. As many studies have suggested that the clinical
manifestations of severe asthma are heterogeneous [4,5],
progressive decline in lung function leading to FAO has
been reported in about 50% of patients with severe
asthma, which is in agreement with our and other
results [6]. FAO is thought to be closely related to the
development of airway remodeling, as well as with
poorer prognosis [21,22]. Identification of risk factors
related to the occurrence of FAO in severe asthma may
therefore be critical because it may provide a foundation
for clarifying the pathogenesis of the disease and may
ultimately lead to effective therapeutic approaches.
Although several studies hada s s e s s e dt h ef a c t o r sc a u s -
ing irreversible airway obstruction in asthmatic patients
of other ethnic groups, the characteristic features of
severe asthma with FAO and the factors associated with
its pathogenesis had not previously been clarified in
Korean patients with severe asthma.
Various clinical characteristics have been proposed as
risk factors for the development of FAO in patients with
severe asthma [19]. Several studies have found that
smoking is one of the most important risk factors for
FAO [15,23]. Other suggested risk factors for FAO
include adult-onset asthma, airway hyperresponsiveness
and, most importantly, sputum eosinophilia [6]. Low
Table 2 Pulmonary function tests of patients with severe asthma
Characteristics FAO (n = 119) RAO (n = 116) P-value
FEV1, initial, predicted % 54.8 ± 19.9 74.3 ± 22.5 <0.001
FEV1/FVC, initial, predicted % 56.3 ± 11.1 77.6 ± 10.6 <0.001
FEV1/FVC, 3 months after enrollment, predicted % 57.2 ± 10.6 80.0 ± 6.7 <0.001
FEV1/FVC, 12 months after enrollment, predicted % 58.9 ± 9.6 80.9 ± 7.1 <0.001
Baseline PC20, mg/dL* 2.7 ± 4.1 5.6 ± 6.4 0.036
*Baseline methacholine bronchial provocation tests were done in 65 subjects:
33 patients with FAO (n = 119), 32 patients with RAO (n = 116).
Abbreviations:
FAO, fixed airway obstruction; RAO, reversible airway obstruction; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; PC20, provocation
concentration that caused a 20% decrease in FEV1.
Data are presented as mean ± SD.
Table 3 Laboratory data in patients with severe asthma
Characteristics FAO (n = 119) RAO (n = 116) P-value
Blood neutrophils,/uL 5161.3 ± 2807.0 4833.4 ± 2493.4 0.514
Blood eosinophils,/uL 320.7 ± 345.8 378.6 ± 373.9 0.468
Blood neutrophils, % 58.8 ± 14.4 57.0 ± 12.4 0.327
Blood eosinophils, % 4.1 ± 4.3 4.9 ± 5.2 0.308
Sputum neutrophils, %* 29.1 ± 24.5 29.2 ± 25.6 0.780
Sputum eosinophils, %* 16.4 ± 21.2 8.8 ± 14.3 0.168
Uric acid, mg/dL 5.4 ± 1.5 5.1 ± 1.6 0.500
CRP, mg/dL 0.8 ± 2.5 0.3 ± 0.7 0.170
Log IgE 2.1 ± 0.6 2.2 ± 0.6 0.475
*Successful sputum counts were done in 64 subjects:
37 patients with FAO (n = 119), 27 patients with RAO (n = 116).
Abbreviations:
FAO, fixed airway obstruction; RAO, reversible airway obstruction; CRP,
C-reactive protein.
Data are presented as mean ± SD.
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risk factor for FAO, suggesting that structural changes
already occur during the early course of the disease [24].
Other possible risk factors for FAO include recurrent
severe asthma exacerbation, higher degree of asthma
severity, male sex [8,25-27], longer disease duration [28],
advanced age and aspirin sensitivity [8]. In agreement
with these findings, we found that longer disease dura-
tion and smoking history were closely associated with
FAO in Koreans with severe asthma.
In the current study, we also found that an absence of
rhinosinusitis was closely associated with FAO in our
patient population. Interestingly, the factor of absence of
rhinosinusitis had not been previously described as a
risk factor for FAO. Rather, patients with severe asthma
were reported to have more severe rhinosinusitis than
were those with mild asthma [1]. Furthermore, uncon-
trolled rhinosinusitis is a well known compounding fac-
tor which is involved with poorly controlled asthma
[29]. Meanwhile, there is a report that the prevalence of
rhinosinusitis has been found to decrease, and asthma
severity to increase, with age [30]. Our finding, of a
reduced prevalence of rhinosinusitis in patients with
more severe asthma, may be due to the spontaneous
regression of rhinosinusitis during the course of asthma.
The relationship between FAO and the absence of rhi-
nosinusitis in patients with severe asthma, however, is
not yet clear, although it may represent a unique feature
of Korean patients with severe asthma.
In the present study, asthmatic patients with FAO
tended to be more non-atopic, although the difference
was not statistically significant. Non-atopic asthma with-
out rhinosinusitis may be a pre-requisite factor for the
development of FAO in our patient cohort, because ato-
pic asthma is usually milder, has an earlier onset and is
more commonly accompanied by other allergic disease
such as allergic rhinosinusitis [1,31,32]. Classification of
severe asthma into several groups through cluster analy-
sis also found that one cluster was characterized by
childhood onset, more atopic and presence of RAO,
while the other cluster consisted of patients with later-
onset disease, less atopic and FAO [4]. Thus, FAO in
severe asthma may be related to the absence of rhinosi-
nusitis due to the non-atopic conditions of the subjects.
Many studies have reported that longer duration of
asthma may lead to irreversible airway obstruction
[28,33,34]. Prolonged airway inflammation may be
related to increased remodeling of the airway walls and
a greater reduction in the airway lumen over time. We
also observed significant correlations between asthma
duration and FAO in multivariate analysis.
In previous reports, advanced age was associated with
the development of FAO [33,35]. Elderly asthma patients
tend to show reduced immediate bronchodilator
responses and decreased reversibility of airway obstruc-
tion after treatment. These results may be caused by the
occurrence of irreversible airway remodeling in elderly
asthma patients, who presumably have longer disease
duration. However, in our study, older age was not an
independent risk factor for FAO.
Sputum eosinophilia is thought to be an important
marker of FAO, suggesting that eosinophilic airway
inflammation may contribute to persistent airflow lim-
itation in patients with severe asthma[36,37]. Eosinophils
can secrete a variety of chemical mediators which may
induce airway remodeling [36,37]. We found, however,
no significant differences between the FAO and RAO
groups in numbers of sputum or blood eosinophils,
although the numbers tended to be higher in the
patients with FAO.
This study had several limitations. First, as it was
observational study in design, the clinical situations of
the patients may have been diverse regarding types of
medications, adherence to medications, familiarity with
a certain inhaler device, and environmental control of
workplaces or home. These might have affected the clin-
ical course and the proportion of FAO, although all
enrolled patients were optimally treated by experts and
with correct medications and were also believed to be
compliant with their prescribed medications. In addi-
tion, FAO was defined one year after enrollment, a rela-
tively short follow-up period. FAO may have been a
Table 4 Factors associated with fixed airway obstruction in patients with severe asthma
Univariate analysis Multivariate analysis
p-value Crude OR (95% CI) p-value Adjusted OR (95% CI)
Smoking more than 5 pack-years < 0.001 3.8 (2.1-7.0) 0.015 6.6 (1.4-30.1)
Asthma more than 15 years 0.064 1.8 (1.0-3.4) 0.028 5.4 (1.2-24.4)
Absence of rhinosinusitis 0.014 2.0 (1.2-3.4) 0.023 3.8 (1.2-12.3)
Age ≥50 years < 0.001 3.2 (1.9-5.6) 0.632 1.6 (0.2-10.4)
Onset age < 40 years 0.018 0.5 (0.3-0.9) 0.893 1.1 (0.2-8.2)
Male sex < 0.001 2.7 (1.6-4.7) 0.907 1.1 (0.3-4.9)
Presence of atopy 0.069 0.5 (0.2-1.1) 0.097 0.4 (0.1-1.2)
Abbreviations: OR, odds ratio; CI, confidence interval.
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the asthmatic airways. Thus, a longer-term follow-up
study is required to determine the risk factors for FAO
in patients with severe asthma.
Another limitation of our study is that the presence or
absence of rhinosinusitis was basically identified by his-
tory-taking and according to patients’ symptoms. As not
all study patients underwent objective measures to con-
firm their diagnosis, such as rhinoscopy, paranasal sinus
radiography or ostiomeatal unit computed tomography,
patients with asymptomatic rhinosinusitis may have
been misclassified in this study. Future studies should
include objective tests to exclude patients with asympto-
matic rhinosinusitis.
As it is not always possible to completely exclude
smoking-related COPD, this may be another important
limitation of this study. Although patients whose major
diagnosis could be COPD were not included in this
study, some of the participants may have belonged to
t h ea s t h m aa n dC O P Do v e r l a ps y n d r o m ep o p u l a t i o n
[38]. Moreover, not only the patients with RAO but also
those with FAO may be heterogeneous in terms of the
reversibility according to the level of airway obstruction.
Although in the current study FAO was defined as exist-
ing only when all three pulmonary function tests, when
performed under stable conditions, showed an FEV1/
FVC ratio < 0.7, considerable heterogeneity in the
patients clinical features is still present even in severe
asthma. Thus, there is an urgent need to clarify the het-
erogeneity of asthma, and further studies should be
conducted.
Finally, our population of patients with severe asthma
might not be representative of all Korean patients with
severe asthma enrolled in the COREA since some clini-
cal features differed between the groups of included and
non-included patients. Hence, further studies with larger
study populations are also needed to confirm our
findings.
In conclusion, this study is the first to report factors
that may be related to persistent airflow limitation in
Koreans with severe asthma. We found that long-
standing asthma and the absence of rhinosinusitis were
more likely to lead to persistent irreversible airway
obstruction. In addition, our findings further demon-
strated that smoking is an important cause of irreversi-
ble airway damages. Further studies are required to
clarify the mechanisms underlying the development of
FAO in Korean subjects with severe asthma.
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